↓ Skip to main content

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Overview of attention for article published in Clinical Cancer Research, March 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
2 news outlets
twitter
7 X users
patent
4 patents
guideline
1 clinical guideline source

Readers on

mendeley
122 Mendeley